Biopharmaceutical company Kintara Therapeutics Inc (Nasdaq: KTRA) announced on Monday that it has commenced a 15-patient clinical trial for REM-001 in cutaneous metastatic breast cancer (CMBC) patients.
The study aims to confirm the planned dose and optimise the trial design, paving the way for a Phase 3 clinical trial initiation.
REM-001, a second-generation photodynamic therapy (PDT) photosensitizer agent, will be evaluated for its efficacy, with the primary endpoint being the Best Overall Objective Response Rate (bORR).
Kintara's dedication to developing novel cancer therapies aligns with its REM-001 Therapy program, addressing unmet medical needs in patients.
Acrivon Therapeutics receives FDA Breakthrough Device designation for ACR-368 OncoSignature assay
Vistagen secures US patent for AV-101 in neuropathic pain treatment
Thermo Fisher Scientific launches international registry for adolescent alopecia areata
hVIVO successfully completes RSV antiviral trial for Shionogi
Valneva secures UK approval for world's first chikungunya vaccine
Alys Pharmaceuticals' IND for ALY-101 approved in US and Canada
NeuroTherapia's Phase 2 Alzheimer's disease trial receives European regulatory approval
NFL Biosciences confirms superior safety profile of NFL-101 in new toxicity study
Avirmax Biopharma completes first cohort of Wet AMD clinical trial
PhaseV collaborates with Alimentiv to address challenges in GI clinical trials
HOPE Therapeutics and NRx Pharmaceuticals select BTIG as financial advisor
Helix unveils clinico-genomic dataset of over 15,000 patients treated with GLP-1 agonists
Roquefort Therapeutics sells Lyramid for USD10.8m equity deal with Pleiades Pharma